The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial

The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial

Background: Cost, adverse events, and long treatment duration can be significant obstacles in treating hepatitis C virus (HCV)-infected individuals. Shortening the treatment regimen can minimize these barriers, thereby enhancing adherence and increasing medication availability to more patients. Meth...

Full description

Bibliographic Details
Main Authors: Ahmad AlEid, Areej Al Balkhi, Adel Qutub, Shahem Abbarh, Abed AlLehibi, Abdullah Almtawa, Nawwaf Al Otaibi, Ahmed AlGhamdi, Adel AlGhamdi, Abdulrahman Alamr, Shameem Ahmad, Khalid Al Sayari, Bashaar Al Ibrahim, Abdullah AlKhathlan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:The Saudi Journal of Gastroenterology
Subjects:
health-related quality of life
hepatitis c genotype 4
elbasvir/grazoprevir
sustained virologic response
Online Access:http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2022;volume=28;issue=3;spage=225;epage=232;aulast=AlEid

Internet

http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2022;volume=28;issue=3;spage=225;epage=232;aulast=AlEid

Similar Items